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ANTIHYPERTENSIVE
DRUGS
BACKGROUND
Hypertensive disorders of pregnancy (HDP) are major causes of severe
morbidity, long-term disability, and death of mothers and babies. Globally, about 10 percent of women experience increased blood pressure
(BP) during pregnancy, and 2-8 percent of pregnancies are complicated
by pre-eclampsia. Among them, 10 percent develop severe pre-eclampsia and eclampsia. About 10-20 percent of all maternal deaths are from
eclampsia, the second leading direct cause of maternal mortality.
Expanding proven, high impact practices is critical to accelerating a
global reduction in maternal and perinatal morbidity and mortality. The
need is especially acute in low- and middle-income countries (LMICs)
of sub-Saharan Africa and South Asia, where 65-85 percent of the populations are rural and have limited access to life-saving care. Sixteen
percent of all maternal deaths in LMICs are from HDP, with women in
LMICs being 300 times more likely to die from eclampsia than those in
developed countries.
The etiology of pre-eclampsia and eclampsia (PE/E) is unclear, but it is
a multi-system disorder impacting cardiovascular and neurological functions. What is clear is PE/E-related deaths are preventable with early detection during antenatal care through BP monitoring and management
with antihypertensive drugs and magnesium sulphate (MgSO4).
MgSO4 is used for preventing and treating convulsions from severe
pre-eclampsia and eclampsia, respectively, and is one of 13 essential
commodities identified by the UN Commission on Life-saving Commodities for Women and Children. However, MgSO4 alone does not address
the complex signs and symptoms that women with pre-eclampsia experience. Although safe, low-cost, and effective, MgSO4 is an anticonvulsant but it does not treat hypertension. If it is not stabilized, there is an
increased risk of major adverse cardiovascular events, such as stroke
and death. It is critical to use antihypertensive drugs to lower high BP.
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MANAGING HYPERTENSION DURING PREGNANCY
Most women with pre-eclampsia have hypertension, meaning the systsolic BP is above 140mmHg and the diastolic BP is above 90mmHg.
Hypertension can be mild (≥140/90 - <150/100mmHg), moderate
(≥150/100 - <160/110mmHg), or severe (≥160/110mmHg). Moderate

Highlights
1. Pre-eclampsia is a condition in
pregnant women marked by an
increase in blood pressure and
protein in urine after 20 weeks
gestation.
2. Eclampsia is a life-threatening
condition characterized by convulsions in women with PE.
3. PE/E and other hypertensive disorders in pregnancy increase the
risk of pre-term births.
4. Providing high quality and regular
(ideally eight contacts) antenatal
care improves the prevention and
early detection of pre-eclampsia
and can prevent its progression to
eclampsia.
5. Prescribing low-dose aspirin and
calcium to at-risk women can prevent pre-eclampsia and eclampsia.
6. Pre-eclampsia and eclampsia can
be managed by administering antihypertensive drugs and magnesium sulphate (MgSO4).
7.

MgSO4 is the safest and most effective treatment for severe PE/E,
and is one of 13 UN Life-Saving
Commodities for Women and
Children.

8. Improved prevention, increased
detection, and effective treatment
of PE/E can prevent unnecessarymaternal and newborn deaths.

and severe hypertension require treatment with antihypertensive drugs.
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A Cochrane systematic review found that antihypertensive drugs
low-er the risk of developing severe hypertension. The WHO
recommends that every health facility have adequate oral and
intravenous antihy-pertensive drugs in the antenatal, labor, and
maternity units. If the sys-tolic blood pressure is 160 mmHg or more
or the diastolic blood pres-sure is 110 mmHg or more, prescribe
antihypertensive drugs. There are four antihypertensive drugs –
labetalol, hydralazine, methyldopa, and nifedipine – that are safe to
use during pregnancy.
Despite being safe, low-cost, effective, and commonly
available, LMICs, countries and programs do not procure antihypertensive drugs in quantities large enough to meet the demand
for managing high BP in pregnancy. However in 2016, members
of Maternal Health Caucus of the Repro-ductive Health Supplies
Coalition agreed anti-hypertensives should be part of the
essential medicines list for maternal health.
Challenges in ensuring that women have access to antihypertensive
drugs to control their BP during pregnancy include the following:
• National task shifting policies do not allow management of HDP
at the primary healthcare (PHC) facility level, even though they are
mandated to administer a loading dose of MgSO4 prior to referral.
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• Stock out of antihypertensive drugs at PHC facilities
• Additional cost of training PHC health workers to monitor BP and
prescribe antihypertensive drugs correctly.
• Lack of support for task shifting from professional bodies.
The problem lies with national policies that enable or prohibit task
shifting to providers at primary healthcare facilities. In many countries,
the administration of a loading dose of MgSO4 to women with PE/E
has been shifted to lower cadre providers (e.g., the community health
extension workers), but the control of hypertension during pregnancy,
including PE/E, is not included in national task shifting policies.

CONCLUSION

10. www.endingeclampsia.org/resources

HDP, including PE/E, is a major cause of maternal and fetal mortality and morbidity globally. To prevent these deaths, early detection of
the disease during pregnancy and appropriate use of antihypertensive drugs (and MgSO4, when indicated) are recommended for women
with severe hypertension during and after pregnancy. It is, therefore,
crucial that the four antihypertensive drugs that are safe to use in
pregnancy - labetalol, hydralazine, methyldopa, and nifedipine - are
included on the essential MNH drug list and distributed to every
health facility in every country.

The Ending Eclampsia project seeks to expand
access to proven,underutilized interventions and
commodities for the prevention, early detection,
and treatment of pre-eclampsia and eclampsia and
strengthen global partnerships.

